Traders bought shares of Baxter International Inc (NYSE:BAX) on weakness during trading hours on Thursday. $81.94 million flowed into the stock on the tick-up and $43.24 million flowed out of the stock on the tick-down, for a money net flow of $38.70 million into the stock. Of all stocks tracked, Baxter International had the 27th highest net in-flow for the day. Baxter International traded down ($1.97) for the day and closed at $70.47
Several brokerages have issued reports on BAX. Barclays began coverage on Baxter International in a research note on Monday. They issued an “underweight” rating and a $73.00 target price for the company. Morgan Stanley upped their target price on Baxter International from $68.00 to $75.00 and gave the stock an “underweight” rating in a research note on Thursday, October 11th. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a research note on Tuesday, September 25th. Argus reaffirmed a “hold” rating on shares of Baxter International in a research note on Tuesday, September 4th. Finally, Citigroup upped their target price on Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 31st. Two analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. Baxter International has a consensus rating of “Hold” and a consensus price target of $77.77.
The company has a market capitalization of $41.19 billion, a PE ratio of 29.02, a P/E/G ratio of 2.08 and a beta of 0.77. The company has a quick ratio of 2.00, a current ratio of 2.62 and a debt-to-equity ratio of 0.39.
In other Baxter International news, Director Carole J. Shapazian sold 5,400 shares of the business’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $72.97, for a total value of $394,038.00. Following the completion of the sale, the director now owns 15,248 shares in the company, valued at $1,112,646.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Giuseppe Accogli sold 17,647 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.27, for a total value of $1,363,583.69. Following the completion of the sale, the senior vice president now owns 59,452 shares of the company’s stock, valued at approximately $4,593,856.04. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Bridgeworth LLC bought a new stake in Baxter International in the second quarter valued at approximately $102,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in Baxter International by 3,088.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,435 shares of the medical instruments supplier’s stock valued at $106,000 after purchasing an additional 1,390 shares during the last quarter. Baker Ellis Asset Management LLC bought a new stake in Baxter International in the second quarter valued at approximately $111,000. Centaurus Financial Inc. bought a new stake in Baxter International in the second quarter valued at approximately $117,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in Baxter International by 84.4% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock valued at $126,000 after purchasing an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 83.08% of the company’s stock.
About Baxter International (NYSE:BAX)
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: Diversification For Individual Investors
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.